

Code:

Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2026 www.cdc.gov/nhsn

Hemovigilance Module Adverse Reaction Post Transfusion Purpura

*Required for saving *Facility ID#: NHSN Adverse Reaction #: **Patient Information** *Patient ID: *Gender: M Other *Date of Birth: / / Gender Identity (Specify): Sex at Birth: M F Unknown Male Female Male-to-female transgender Female-to-male transgender Identifies as non-conforming Other Asked but unknown Social Security #: Medicare #: Secondary ID: Middle Name: _____ Last Name: _____ First Name: ___ Race (Specify): (Select all that apply): American Indian or Alaska Native Ethnicity (Specify): Asian Hispanic or Latino Black or African American Not Hispanic or Latino Middle Eastern or North African Unknown Native Hawaiian or Pacific Islander Declined to respond White Unknown Declined to respond Interpreter Needed: Yes Preferred Language (Specify): Declined to Respond Unknown *Blood Group: A- A+ O-O+ Blood type not done Transitional ABO / Transitional Transitional ABO / Rh + Transitional ABO / Rh -Group A/Transitional Group B/Transitional Group O/Transitional Rh Group AB/Transitional Rh Rh Rh **Patient Medical History** List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions) Description: _____ Code: Code: _____ Description: Code: Description: List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions) Code: Description:

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.314 Rev. 3, v9.2

Description:

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



List the patients contained contained at the time of the translation related to the daverse	SALLITIVELYVORK		www.cac.gov/iiiioii
reaction. (Use ICD-10 Diagnostic codes/descriptions) Code: Description: Code: Description:	Code:	Description:	· · · · · · · · · · · · · · · · · · ·
Code: Description:			UNKNOWN NONE
	Code:	Description:	
Code: Description:	Code:	Description:	
	Code:	Description:	



List the patient's relevant med performed during the current codes/descriptions)	dical procedure including past hospital or outpatient stay. <i>(U</i>		es to be UNKNOWN NONE
Code:	Description:		
Code:			
Code:			
Additional Information			
Transfusion History			
Has the patient received a pro	evious transfusion?	YES NO	UNKNOWN
	VB RBC Platelet	Plasma Cryopre	
Date of Transfusion:	/ UNK	NOWN	
Was the patient's adverse r	eaction transfusion-related?	YES	NO
If yes, provide information a	bout the transfusion adverse	reaction.	
Type of transfusion adverse	reaction: Allergic	AHTR DHTR	DSTR FNHTR
HTR TTI	PTP TACO TAD	TA-GVHD TR	ALI UNKNOWN
OTHER Specify			
Reaction Details		_	
*Date reaction occurred:/_	/ *Time reaction or	ccurred: ::_	Time unknown
*Facility location where patien	t was transfused:		
Is this reaction associated with a	n incident? Yes	No If Yes, Incider	nt #:
Investigation Results			
* Post transfusion purpura	(PTP)		
*Case Definition			
Check all that occurred aft Alloantibodies in the p development of thron	atient directed against HPA o	r other platelet specific anti	igen detected at or after
Thrombocytopenia (i.e	e., decrease in platelets to less	s than 20% of pre-transfusi	on count).
Decrease in platelets t	to levels between 20% and 80	% of pre-transfusion count	t.
Check all that apply:			
	laboratory findings and/or infolatelet count to less than 80% e.		
Other signs and symptoms: (cl	neck all that apply)		
Generalized:	Chills/rigors	Fever	Nausea/vomiting
Cardiovascular:	Blood pressure decrease	Shock	
Cutaneous:	Edema	Flushing	Jaundice
	Other rash	Pruritus (itching)	Urticaria (hives)
Hemolysis/Hemorrhage:	Disseminated intravascul	ar coagulation Hem	oglobinemia
	Positive antibody screen	🗆	
Pain:		ack pain Flank pain	Infusion site pain
Renal:	Hematuria	Hemoglobinuria	Oliguria



Respiratory:	Bilateral infiltrates on chest x-ray	Bronchospasm	Cough
	Hypoxemia Shor	tness of breath	
Other: (specify)			
*Severity			
Did the patient receive or ex	xperience any of the following?		
No treatment require	ed Symptomatic	c treatment only	
Hospitalization, inlcu	ıding prolonged hospitalization	Life-threatening	g reaction
Disability and/or inca	apacitation Congenital a	anomaly or birth defect(s) of the fetus
Other medically impo	ortant conditions Death	Unknown or no	t stated
*Imputability			
Which best describes the re	lationship between the transfusion and	the reaction?	
	conditions to explain thrombocytopenia		
There are other poter likely cause.	ntial causes present that could explain	thrombocytopenia, but t	ransfusion is the most
Alternate explanation	s for thrombocytopenia are more likely	, but transfusion cannot	be ruled out.
Evidence is clearly in	favor of a cause other than the transfus	sion, but transfusion can	not be excluded.
	vidence beyond reasonable doubt of a		
	een the adverse reaction and the trans		
Did the transfusion occur at			
	,		
	r in relation to the transfusion?		
Occurred 5-12 days p			
	or more than 12 days post-transfusion		
Module-generated Designations for some de		a automotically acciona	ol in the All ICAL
	finition, severity, and imputability will b in the corresponding investigation resu		a in the NASN
•	se definition designation?	YES	NO
^Please indicate your desig			
*Do you agree with the <u>se</u>	<u>verity</u> designation?	YES	NO
^Please indicate your desig	nation		
*Do you agree with the <u>im</u>	putability designation?	YES	NO
^Please indicate your desig	nation		
Patient Treatment			
Did the patient receive treatm	ent for the transfusion reaction?	YES NO	UNKNOWN
If yes, select treatment(s):			
Medication (Select the	e type of medication)		
A	Antihiotominos	Due seale e 33 e	tor Diversit
Antipyretics	Antihistamines Inotropes/Vasopress	sors Bronchodila	tor Diuretics
Intravenous Immunoglobulin	Intravenous steroids	Corticosteroids	Antibiotics
			AHRINIORIC2
Antithymocyte g	lobulin Cyclosporin O	ther	



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2026

SAFETY NET	work Jime resuscitation (Intr	avenous colloid	ls or crystalloids)			.cdc.gov/nhsn
Res	piratory support <i>(Sele</i> Mechanical ventilati		upport) nvasive ventilation	Oxyger	١	
Ren	al replacement therap Hemodialysis	oy <i>(Select the ty</i> Peritoneal	pe of therapy) Continuous Ver	no-Venous Hem	nofiltration	
Oth	ebotomy er Specify:					
Outcome						
Cause		. —	ion to death:	Minor or no quelae	□ Not deter	
Component	Details					
	cular unit implicated	d in (i.e., respo		dverse	Yes No	N/A
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group of unit	Implicate d Unit?
^IMPLICATED	UNIT					
	ISBT-128 Codabar	Entire unit Partial unitmL	 		B+ AB- AB+ O- O+ N/A	
!! !!	ISBT-128 Codabar	Entire unit Partial unitmL			A- A+ B- B+ AB- AB+ O- O+ N/A	
Custom Field	ds					
Label	<u></u>		Label			
		'				
Comments						

